Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Translational potential of preclinical trials of neuroprotection through pharmacotherapy for spinal cord injury.

Tator CH, Hashimoto R, Raich A, Norvell D, Fehlings MG, Harrop JS, Guest J, Aarabi B, Grossman RG.

J Neurosurg Spine. 2012 Sep;17(1 Suppl):157-229. doi: 10.3171/2012.5.AOSPINE12116. Review.

PMID:
22985382
2.

North American Clinical Trials Network for the Treatment of Spinal Cord Injury: goals and progress.

Grossman RG, Toups EG, Frankowski RF, Burau KD, Howley S.

J Neurosurg Spine. 2012 Sep;17(1 Suppl):6-10. doi: 10.3171/2012.4.AOSPINE1294.

PMID:
22985365
3.

Riluzole for acute traumatic spinal cord injury: a promising neuroprotective treatment strategy.

Wilson JR, Fehlings MG.

World Neurosurg. 2014 May-Jun;81(5-6):825-9. doi: 10.1016/j.wneu.2013.01.001. Epub 2013 Jan 4. Review.

PMID:
23295632
4.

Pharmacology of riluzole in acute spinal cord injury.

Chow DS, Teng Y, Toups EG, Aarabi B, Harrop JS, Shaffrey CI, Johnson MM, Boakye M, Frankowski RF, Fehlings MG, Grossman RG.

J Neurosurg Spine. 2012 Sep;17(1 Suppl):129-40. doi: 10.3171/2012.5.AOSPINE12112.

PMID:
22985379
5.

Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial.

Fehlings MG, Wilson JR, Frankowski RF, Toups EG, Aarabi B, Harrop JS, Shaffrey CI, Harkema SJ, Guest JD, Tator CH, Burau KD, Johnson MW, Grossman RG.

J Neurosurg Spine. 2012 Sep;17(1 Suppl):151-6. doi: 10.3171/2012.4.AOSPINE1259.

PMID:
22985381
6.

Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside.

Nagoshi N, Nakashima H, Fehlings MG.

Molecules. 2015 Apr 29;20(5):7775-89. doi: 10.3390/molecules20057775. Review.

7.

Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury.

Hawryluk GW, Rowland J, Kwon BK, Fehlings MG.

Neurosurg Focus. 2008;25(5):E14. doi: 10.3171/FOC.2008.25.11.E14. Review.

PMID:
18980474
8.

Concise Review: Bridging the Gap: Novel Neuroregenerative and Neuroprotective Strategies in Spinal Cord Injury.

Ahuja CS, Fehlings M.

Stem Cells Transl Med. 2016 Jul;5(7):914-24. doi: 10.5966/sctm.2015-0381. Epub 2016 Apr 29. Review.

9.

Translational research in spinal cord injury: a survey of opinion from the SCI community.

Kwon BK, Hillyer J, Tetzlaff W.

J Neurotrauma. 2010 Jan;27(1):21-33. doi: 10.1089/neu.2009.1048. Review.

PMID:
19751098
10.

Nanowired drug delivery to enhance neuroprotection in spinal cord injury.

Tian ZR, Sharma A, Nozari A, Subramaniam R, Lundstedt T, Sharma HS.

CNS Neurol Disord Drug Targets. 2012 Feb;11(1):86-95. Review.

PMID:
22385571
11.

A grading system to evaluate objectively the strength of pre-clinical data of acute neuroprotective therapies for clinical translation in spinal cord injury.

Kwon BK, Okon EB, Tsai E, Beattie MS, Bresnahan JC, Magnuson DK, Reier PJ, McTigue DM, Popovich PG, Blight AR, Oudega M, Guest JD, Weaver LC, Fehlings MG, Tetzlaff W.

J Neurotrauma. 2011 Aug;28(8):1525-43. doi: 10.1089/neu.2010.1296. Epub 2010 Oct 18. Review.

12.

Lack of neuroprotective effects of simvastatin and minocycline in a model of cervical spinal cord injury.

Lee JH, Tigchelaar S, Liu J, Stammers AM, Streijger F, Tetzlaff W, Kwon BK.

Exp Neurol. 2010 Sep;225(1):219-30. doi: 10.1016/j.expneurol.2010.06.018. Epub 2010 Jun 28.

PMID:
20599974
13.

Steroids for acute spinal cord injury.

Bracken MB.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD001046. doi: 10.1002/14651858.CD001046.pub2. Review.

PMID:
22258943
14.

Investigational drugs for the treatment of spinal cord injury: review of preclinical studies and evaluation of clinical trials from Phase I to II.

Nagoshi N, Fehlings MG.

Expert Opin Investig Drugs. 2015 May;24(5):645-58. doi: 10.1517/13543784.2015.1009629. Epub 2015 Feb 3. Review.

PMID:
25645889
15.

A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury.

Kwon BK, Okon E, Hillyer J, Mann C, Baptiste D, Weaver LC, Fehlings MG, Tetzlaff W.

J Neurotrauma. 2011 Aug;28(8):1545-88. doi: 10.1089/neu.2009.1149. Epub 2010 Apr 14. Review.

17.

Limiting spinal cord injury by pharmacological intervention.

Priestley JV, Michael-Titus AT, Tetzlaff W.

Handb Clin Neurol. 2012;109:463-84. doi: 10.1016/B978-0-444-52137-8.00029-2. Review.

PMID:
23098731
18.

Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury.

Simard JM, Tsymbalyuk O, Keledjian K, Ivanov A, Ivanova S, Gerzanich V.

Exp Neurol. 2012 Jan;233(1):566-74. doi: 10.1016/j.expneurol.2011.11.044. Epub 2011 Dec 8.

19.

Spinal cord injury: a systematic review of current treatment options.

Cadotte DW, Fehlings MG.

Clin Orthop Relat Res. 2011 Mar;469(3):732-41. doi: 10.1007/s11999-010-1674-0. Review.

20.

Magnesium sulfate treatment in experimental spinal cord injury: emphasis on vascular changes and early clinical results.

Kaptanoglu E, Beskonakli E, Solaroglu I, Kilinc A, Taskin Y.

Neurosurg Rev. 2003 Oct;26(4):283-7. Epub 2003 May 29.

PMID:
12783273

Supplemental Content

Support Center